BETA
Your AI-Trained Oncology Knowledge Connection!
Expert perspectives on treatment considerations for ponatinib in patients with chronic myeloid leukemia.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Ziftomenib Shows MRD-Negative Responses in Pretreated NPM1+ AML
The KOMET-001 trial meets its primary end point of CR/CRh rate among patients with NPM1-mutated acute myeloid leukemia.
Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy
Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.
Zanubrutinib Shows Sustained Efficacy in Chronic Lymphocytic Leukemia
With longer-term follow-up, investigators observed no new safety signals for zanubrutinib in patients with CLL or SLL harboring 17p deletions.
Immunotherapy Approaches in AML
Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.
3 Things You Should Know About Advances in CLL Management
Care for patients with chronic lymphocytic leukemia continues to evolve via novel targeted therapies. Here are 3 things every cancer care specialist should know about treating CLL.
Revumenib Yields Meaningful Benefit in NPM1-Mutated Acute Myeloid Leukemia
Phase 2 data support the potential of revumenib to advance the standard of care for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.